The development of dBET6‐based formulations may contribute to efficient cancer therapy by BRD4 degradation, which exhibits a more profound effect independent of its catalytic activity on gene transcription and cell growth regulation than BRD4 inhibition while enabling lower drug exposure and less frequent dosing.[13, 26]. The gene discussed is BRD4; the disease is cancer.